Digoxin and cognitive performance in patients with heart failure: a cohort, pharmacoepidemiological survey.

BACKGROUND: Cognitive dysfunction is a prevalent condition among patients with heart failure (HF), and is independently associated with disability and mortality. A large study of patients with atrial fibrillation incidentally demonstrated superior cognitive performance among participants who receive...

Descripción completa

Detalles Bibliográficos
Publicado en:Drugs & Aging Vol. 26; no. 2; pp. 103 - 113
Autores principales: Laudisio A, Marzetti E, Pagano F, Cocchi A, Bernabei R, Zuccalà G
Formato: research tables/charts Journal Article
Publicado: Springer Nature 2009
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105474952&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105474952
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1170229X
        C5B
      jtl: Drugs & Aging
      issn: 1170229X
      maglogo: N
    pubinfo:
      dt: 2009
      vid: 26
      iid: 2
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        105474952
        105474952
        2010220431
        10.2165/0002512-200926020-00002
        NLM19220067
        105474952
      ppf: 103
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Digoxin and cognitive performance in patients with heart failure: a cohort, pharmacoepidemiological survey.
      aug:
        au:
          Laudisio A
          Marzetti E
          Pagano F
          Cocchi A
          Bernabei R
          Zuccalà G
        affil: Department of Gerontology, Geriatrics, and Physiatrics, Catholic University of Medicine, Rome, Italy.
      sug:
        subj:
          Antiarrhythmia Agents Therapeutic Use
          Cognition Drug Effects
          Digoxin Therapeutic Use
          Heart Failure Drug Therapy
          Aged
          Aged, 80 and Over
          Analysis of Variance
          Chi Square Test
          Descriptive Statistics
          Female
          Funding Source
          Heart Failure Complications
          Italy
          Kruskal-Wallis Test
          Logistic Regression
          Male
          Middle Age
          Human
          Aged: 65+ years
          Aged, 80 & over
          Middle Aged: 45-64 years
          Female
          Male
      ab: BACKGROUND: Cognitive dysfunction is a prevalent condition among patients with heart failure (HF), and is independently associated with disability and mortality. A large study of patients with atrial fibrillation incidentally demonstrated superior cognitive performance among participants who received digoxin. Interestingly, endogenous cerebral digoxin influences neuronal Na(+)-dependent transport of calcium and amino acids, as well as the release and reuptake of several neurotransmitters involved in cognitive functioning. OBJECTIVE: To assess whether treatment with digoxin might improve cognition in patients with HF. METHODS: This pharmacoepidemiological cohort study included hospitalized elderly people (age >/=65 years) from the GIFA (Gruppo Italiano di Farmacoepidemiologia nell'Anziano [Italian Group of Pharmacoepidemiology in the Elderly]) study. The GIFA study included 13 598 patients (1590 with a verified diagnosis of HF) without cerebrovascular or Alzheimer's disease. The main outcome measure was cognitive performance, which was assessed on admission and immediately before discharge using the Hodkinson Abbreviated Mental Test. The diagnosis of HF was verified by the study investigators. RESULTS: Among participants with HF, cognitive performance improved in 25% of 1172 participants who received digoxin compared with 16% of remaining patients (p < 0.0001). Among participants without HF, cognition improved in 23% of 2431 patients receiving digoxin compared with 17% of untreated patients (p < 0.0001). According to logistic regression analysis, the probability (odds ratio) of improving cognitive performance associated with administration of digoxin was 1.69 (95% CI 1.20, 2.38) among patients with HF, and 1.13 (95% CI 0.98, 1.31) among patients without HF, after adjusting for potential confounders. Analysis of the interaction term 'use of digoxin by diagnosis of HF' in fully adjusted logistic regression confirmed (p = 0.018) that the association between use of digoxin and improving cognitive performance varied according to diagnosis of HF. CONCLUSION: Treatment with digoxin might selectively improve cognitive performance among older patients with HF.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N